财务表现 - 公司2025年第二季度营收达36.8亿美元，同比增长3.6% [1] - 每股收益(EPS)为12.89美元，高于去年同期的11.56美元 [1] - 营收超出Zacks共识预期9.91%，EPS超出预期60.52% [1] - 过去一个月股价回报率为-0.4%，同期标普500指数上涨2.3% [3] 产品收入 - Eylea美国市场收入11.5亿美元，同比下降25.2%，但超出分析师预期11.6% [4] - Praluent美国市场收入6580万美元，同比增长17.3%，超出分析师预期20.6% [4] - Libtayo全球收入3.765亿美元，同比增长26.6%，超出分析师预期16.8% [4] - Kevzara全球收入1.522亿美元，同比增长38.7%，超出分析师预期31% [4] 合作收入 - 与拜耳合作收入4.15亿美元，同比增长10.6%，超出分析师预期6.8% [4] - 与赛诺菲合作收入14.4亿美元，同比增长26%，超出分析师预期5.9% [4] - 总合作收入18.6亿美元，同比增长22.1%，超出分析师预期7.5% [4] 其他财务指标 - 其他收入1.839亿美元，同比大幅增长76%，超出分析师预期46.7% [4] - 净产品销售额16.3亿美元，同比下降15%，但超出分析师预期11.6% [4] - Eylea全球总收入21.3亿美元，同比下降13%，但超出分析师预期50% [4]

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short- term price performance of a stock. While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into an ...

Wall Street analysts expect Regeneron (REGN) to post quarterly earnings of $8.76 per share in its upcoming report, which indicates a year-over-year decline of 8.3%. Revenues are expected to be $3.25 billion, up 3.3% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 6.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Ahead of a company's earnings ...